Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Sarcopenic Obesity: early-phase trial registry

1 of 3 indexed Sarcopenic Obesity trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #5,209 of 28,707 conditions by registered trial count.

3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count

Sarcopenic Obesity: 3 US clinical trials tracked, 1 recruiting.

Sarcopenic Obesity is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Sara Espinoza, running 1 of these trials.

Enrollment posture brief

Registry condition sarcopenic-obesity

OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Sarcopenic Obesity (this)33%
Open-enrollment share among volume-matched conditions near Sarcopenic Obesity

Sarcopenic Obesity lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Sarcopenic Obesity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Sarcopenic Obesity is recruiting below its size-band peers.

    1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Sara Espinoza 1 trials
Immunis 1 trials
Mayo Clinic 1 trials

Named interventions

Most-linked intervention names on Sarcopenic Obesity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo nasal spray Drug
1 trials
IMM01-STEM alternating with placebo (saline) Biological
1 trials
IMM01-STEM Biological
1 trials
MAsS Diagnostic test
1 trials
Oxytocin nasal spray Drug
1 trials
Placebo Other
1 trials

US sites by state

Facility locations filed on Sarcopenic Obesity trials. A trial with sites in several states counts in each.

Texas 1 trials
Kansas 1 trials
California 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Sarcopenic Obesity page

3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Sarcopenic Obesity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Sara Espinoza sponsors the most Sarcopenic Obesity trials on record, review their full trial history before evaluating a specific study. See Sara Espinoza's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Sarcopenic Obesity condition card totals 3 registered trials; most-linked intervention Placebo nasal spray; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.